{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:34:32Z","timestamp":1789616072973,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.bioorg.2021.104890","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T21:28:07Z","timestamp":1617830887000},"page":"104890","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of new pyrimidine-5-carbonitrile derivatives bearing 1,3-thiazole moiety as novel anti-inflammatory EGFR inhibitors with cardiac safety profile"],"prefix":"10.1016","volume":"111","author":[{"given":"Salah A.","family":"Abdel-Aziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab S.","family":"Taher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gihan F.","family":"Asaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham A.M.","family":"Gomaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawal A.","family":"El-Koussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahaa G.M.","family":"Youssif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2021.104890_b0005","doi-asserted-by":"crossref","unstructured":"M.G. Netea, F. Balkwill, M. Chonchol, F. Cominelli, M.Y. Donath, E.J. Giamarellos-Bourboulis, D. Golenbock, M.S. Gresnigt, M.T. Heneka, H.M. Hoffman, R. Hotchkiss, L.A.B. Joosten, D.L. Kastner, M. Korte, E. Latz, P. Libby, T. Mandrup-Poulsen, A. Mantovani, K.H.G. Mills, K.L. Nowak, L.A. O'Neill, P. Pickkers, T. van der Poll, P.M. Ridker, J. Schalkwijk, D.A. Schwartz, B. Siegmund, C.J. Steer, H. Tilg J.W.M. van der Meer, F.L. van de Veerdonk, C.A. Dinarello, A guiding map for inflammation, Nat. Immunol. 18 (2017) 826\u2013831.","DOI":"10.1038\/ni.3790"},{"key":"10.1016\/j.bioorg.2021.104890_b0010","doi-asserted-by":"crossref","unstructured":"H. Zhang, A. Berezov, Q. Wang, G. Zhang, J. Drebin, R. Murali, M.I. Greene, ErbB receptors: from oncogenes to targeted cancer therapies, J. Clin. Invest. 117 (2207) 2051-2058.","DOI":"10.1172\/JCI32278"},{"key":"10.1016\/j.bioorg.2021.104890_b0015","doi-asserted-by":"crossref","first-page":"8690","DOI":"10.1016\/j.biomaterials.2013.07.100","article-title":"Epidermal growth factor receptor targeting in cancer: a review of trends and strategies","volume":"34","author":"Yewale","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.bioorg.2021.104890_b0020","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.2174\/1389557516666160321114917","article-title":"Review on EGFR inhibitors: critical updates","volume":"16","author":"Davinder","year":"2016","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104890_b0025","first-page":"373","article-title":"Lung cancer: a new generation of EGFR inhibition","volume":"12","author":"Killock","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2021.104890_b0030","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1677\/erc.1.00600","article-title":"Epidermal growth factor receptor inhibition strategies in oncology","volume":"11","author":"Harari","year":"2004","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bioorg.2021.104890_b0035","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1158\/1078-0432.CCR-05-1554","article-title":"The epidermal growth factor receptor pathway: a model for targeted therapy","volume":"12","author":"Scaltriti","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2021.104890_b0040","doi-asserted-by":"crossref","first-page":"54281","DOI":"10.1039\/C7RA11273D","article-title":"Combined effect of tris(2-chloroethyl)phosphate and benzo (a) pyrene on the release of IL-6 and IL-8 from HepG2 cells via the EGFR-ERK1\/2 signaling pathway","volume":"7","author":"Zhang","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2021.104890_b0045","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/mi.2017.120","article-title":"Respiratory syncytial virus activates epidermal growth factor receptor to suppress interferon regulatory factor 1-dependent interferon-lambda and antiviral defense in airway epithelium","volume":"11","author":"Kalinowski","year":"2018","journal-title":"Mucosal. Immunol."},{"key":"10.1016\/j.bioorg.2021.104890_b0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028216","article-title":"Activation of epidermal growth factor receptor is required for NTHi-induced NF-kappaB-dependent inflammation","volume":"6","author":"Xu","year":"2011","journal-title":"PloSone"},{"key":"10.1016\/j.bioorg.2021.104890_b0055","doi-asserted-by":"crossref","first-page":"8578","DOI":"10.1038\/s41598-017-09122-3","article-title":"EGFR is a pivotal regulator of thrombin-mediated inflammation in primary human nucleus pulposus culture","volume":"7","author":"Huang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2021.104890_b0060","doi-asserted-by":"crossref","first-page":"24580","DOI":"10.1038\/srep24580","article-title":"EGFR inhibition blocks palmitic acid-induced inflammation in cardiomyocytes and prevents hyperlipidemia-induced cardiac injury in mice","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2021.104890_b0065","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1742-2094-9-178","article-title":"Inhibition of EGFR\/MAPK signaling reduces microglial inflammatory response and the associated secondary damage in rats after spinal cord injury","volume":"9","author":"Qu","year":"2012","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.bioorg.2021.104890_b0070","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/1568010054022024","article-title":"Macrophages in inflammation","volume":"4","author":"Fujiwara","year":"2005","journal-title":"Curr. Drug Targets Inflamm. Allergy"},{"key":"10.1016\/j.bioorg.2021.104890_b0075","first-page":"A3274","article-title":"Novel role of epidermal growth factor receptor in macrophages","author":"Mulenos","year":"2017","journal-title":"B36. Macrophages: Basic and Translational Studies, American Thoracic Society"},{"key":"10.1016\/j.bioorg.2021.104890_b0080","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1172\/JCI83585","article-title":"EGFR regulates macrophage activation and function in bacterial infection","volume":"126","author":"Hardbower","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2021.104890_b0085","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/ATVBAHA.117.309927","article-title":"Selective EGFR (Epidermal Growth Factor Receptor) deletion in myeloid cells limits atherosclerosis-brief report","volume":"38","author":"Zeboudj","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bioorg.2021.104890_b0090","doi-asserted-by":"crossref","first-page":"45917","DOI":"10.1038\/srep45917","article-title":"Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress","volume":"8","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2021.104890_b0095","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1007\/s11164-015-2281-1","article-title":"One-pot synthesis and in vivo biological evaluation of new pyrimidine privileged scaffolds as potent anti-inflammatory agents","volume":"42","author":"Undare","year":"2016","journal-title":"Res. Chem. Intermed."},{"key":"10.1016\/j.bioorg.2021.104890_b0100","doi-asserted-by":"crossref","unstructured":"Anjos J.V.d., Srivastava R.M., Costa-Silva J.H., Scotti L., Scotti M.T., Wanderley A. G., Leite E.S., Melo S.J.d., Junior F.J., Comparative computational studies of 3, 4- dihydro-2, 6-diaryl-4-oxo-pyrimidine-5-carbonitrile derivatives as potential antinociceptive agents, Molecules, 17 (2012) 809\u2013819.","DOI":"10.3390\/molecules17010809"},{"key":"10.1016\/j.bioorg.2021.104890_b0105","doi-asserted-by":"crossref","unstructured":"Silva J.B.P.d., Ramos M.N., Barros Neto B.d., Melo S.J.d., Falc\u0303ao E.P.d.S., Catanho M.T.J., Quantitative structure-activity relationships (QSAR) of 4-amino-2, 6- diarylpyrimidine-5-carbonitriles with anti-inflammatory activity, J. Braz. Chem. Soc., 19 (2008) 337\u2013343.","DOI":"10.1590\/S0103-50532008000200021"},{"key":"10.1016\/j.bioorg.2021.104890_b0110","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.ejmech.2011.02.052","article-title":"Novel dihydropyrimidines and its pyrazole derivatives: synthesis and pharmacological screening","volume":"46","author":"Ramesh","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104890_b0115","first-page":"1077","article-title":"Anti-inflammatory and antimicrobial activity of 4, 5-dihydropyrimidine-5-carbonitrile derivatives: their synthesis and spectral elucidation","volume":"69","author":"Alam","year":"2012","journal-title":"Acta Pol. Pharm."},{"key":"10.1016\/j.bioorg.2021.104890_b0120","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejmech.2012.03.050","article-title":"New quinazolinone\u2013pyrimidine hybrids: synthesis, anti-inflammatory, and ulcerogenicity studies","volume":"53","author":"Abbas","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104890_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104555","article-title":"Design and synthesis of pyrimidine-5-carbonitrile hybrids as COX-2 inhibitors: Anti-inflammatory activity, ulcerogenic liability, histopathological and docking studies","volume":"108","author":"Alfayomy","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.104890_b0130","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/1097-0142(197304)31:4<903::AID-CNCR2820310422>3.0.CO;2-N","article-title":"A clinical review of bleomycin-a new antineoplastic agent","volume":"31","author":"Blum","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2021.104890_b0135","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1158\/1078-0432.CCR-09-2236","article-title":"Voreloxin, a first-in-class anticancer quinolone derivative in relapsed\/refractory solid tumors: a report on two dosing schedules","volume":"16","author":"Advani","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2021.104890_b0140","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1200\/JCO.2004.12.001","article-title":"Epothilones: mechanism of action and biologic activity","volume":"22","author":"Goodin","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2021.104890_b0145","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2174\/1381612013397410","article-title":"The epothilones, eleutherobins and related types of molecules","volume":"7","author":"Stachel","year":"2001","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bioorg.2021.104890_b0150","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.clinthera.2007.11.005","article-title":"Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"29","author":"Steinberg","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bioorg.2021.104890_b0155","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-3-642-01222-8_7","article-title":"Dasatinib","volume":"184","author":"Lindauer","year":"2010","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.bioorg.2021.104890_b0160","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/FTD.0b013e3181f4d9c5","article-title":"Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events","volume":"32","author":"Shayani","year":"2010","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.bioorg.2021.104890_b0165","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.1016\/j.bmcl.2012.08.095","article-title":"Substituted thiazoles VII. Synthesis and antitumor activity of certain 2-(substituted amino)-4-phenyl-1,3-thiazole analogs","volume":"22","author":"Hassan","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2021.104890_b0170","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1080\/10426500802446181","article-title":"Synthesis and anticancer activities of some thiazole derivatives","volume":"184","author":"Kayagil","year":"2009","journal-title":"Phosphorus Sulfur Silicon Relat. Elem."},{"key":"10.1016\/j.bioorg.2021.104890_b0175","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/jps.2600590316","article-title":"Potential antineoplastics: 1-thiocarbamoyl-3-methyl-4-arylhydrazono-2-pyrazolin-5-one, 2-amino-4-phenyl-5-arylazothiazoles, and N-phenyl-N0-2 (4-phenyl-5-arylazo- thiazolyl) thiocarbamides","volume":"59","author":"Garg","year":"1970","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2021.104890_b0180","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hc.20256","article-title":"Synthesis and antitumor activity evaluation of some Schiff bases derived from 2-aminothiazole derivatives","volume":"18","author":"Zhou","year":"2007","journal-title":"Heteroatom Chem."},{"key":"10.1016\/j.bioorg.2021.104890_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103811","article-title":"A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy","volume":"99","author":"Ayati","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.104890_b0190","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4067\/S0717-97072010000200021","article-title":"Synthesis and biological evaluation of some substituted amino thiazole derivatives","volume":"55","author":"Prajapati","year":"2010","journal-title":"J. Chil. Chem. Soc."},{"key":"10.1016\/j.bioorg.2021.104890_b0195","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5923\/j.ajoc.20120203.06","article-title":"Synthesis, characterization and antimicrobial activities of some thiazole derivatives","volume":"2","author":"Sharshira","year":"2012","journal-title":"Am. J. Org. Chem."},{"key":"10.1016\/j.bioorg.2021.104890_b0200","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1055\/s-1979-28650","article-title":"A one-step synthesis of 4-oxo-2-thioxopyrimidine derivatives by the ternary condensation of ethyl cyanoacetate, aldehydes, and thiourea","author":"Kambe","year":"1979","journal-title":"Synthesis"},{"key":"10.1016\/j.bioorg.2021.104890_b0205","doi-asserted-by":"crossref","unstructured":"M.H. Abdelrahman, B.G.M. Youssif, M.A. abdelgawad, A.H. Abdelazeem, H.M. Ibrahim, A.A. Moustafa, L. Treamblu, S.N.A. Bukhari. Synthesis, Biological Evaluation, Docking Study and Ulcerogenicity Profiling of Some Novel Quinoline-2-Carboxamides as Dual COXs\/LOX Inhibitors Endowed with Anti-Inflammatory Activity. Eur. J. Med. Chem. 127 (2017) 972-985.","DOI":"10.1016\/j.ejmech.2016.11.006"},{"key":"10.1016\/j.bioorg.2021.104890_b0210","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bioorg.2019.02.043","article-title":"Novel aryl carboximidamide and 3-aryl-1,2,4-oxadiazole analogues of naproxen as dual selective COX-2\/15-LOX inhibitors: Design, synthesis and docking studies","volume":"85","author":"Youssif","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.104890_b0215","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jscs.2012.01.002","article-title":"Modulation of the pharmacological properties of meloxicam by octreotide in rats","volume":"19","author":"El-Awdan","year":"2015","journal-title":"J. Saudi Chem. Soc."},{"key":"10.1016\/j.bioorg.2021.104890_b0220","first-page":"217","article-title":"effect of encapsulation of flufenamic acid with acrylic resins on its bioavilability and gastric ulcerogenc activity in rats","volume":"29","author":"Meshali","year":"1983","journal-title":"Acta Pharm. Technol."},{"key":"10.1016\/j.bioorg.2021.104890_b0225","first-page":"92","article-title":"evaluation of antiulcer activity of zizyhus oenoplia (L) mill. Root in rats","volume":"4","author":"Suryakant","year":"2011","journal-title":"Asian J. Pharm. Clin. Res."},{"key":"10.1016\/j.bioorg.2021.104890_b0230","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ejmech.2019.03.052","article-title":"New pyrazole derivatives: Synthesis, anti-inflammatory activity, cycloxygenase inhibition assay and evaluation of mPGES","volume":"171","author":"Hassan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104890_b0235","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/239310","article-title":"Prostaglandins and rheumatoid arthritis","volume":"2012","author":"Fattahi","year":"2012","journal-title":"Arthritis"},{"key":"10.1016\/j.bioorg.2021.104890_b0240","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s10787-020-00685-8","article-title":"Mechanisms involved in the antinociceptive and anti-inflammatory effects of a new triazole derivative: 5-[1-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl]-1H-tetrazole","volume":"28","author":"Cardoso","year":"2020","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.bioorg.2021.104890_b0245","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bioorg.2021.104890_b0250","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.berh.2006.06.002","article-title":"Problems encountered during anti-tumour necrosis factor therapy","volume":"20","author":"Desai","year":"2006","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.bioorg.2021.104890_b0255","article-title":"A greener protocol for the synthesis of phosphorochalcogenoates: Antioxidant and free radical scavenging activities","volume":"213","author":"Mailahn","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104890_b0260","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0003-2697(79)90738-3","article-title":"Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction","volume":"95","author":"Ohkawa","year":"1979","journal-title":"Anal. Biochem."},{"issue":"3","key":"10.1016\/j.bioorg.2021.104890_b0265","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1574-695X.2007.00329.x","article-title":"The role of nitric oxide in inflammatory reactions","volume":"51","author":"Tripathi","year":"2007","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"10.1016\/j.bioorg.2021.104890_b0270","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jep.2008.01.005","article-title":"Inhibition of inducible nitric oxide production and iNOS protein expression in lipopolysaccharide-stimulated rat aorta and Raw 264.7 macrophages by ethanol extract of a Chinese herbal medicine formula (RCM-101) for allergic rhinitis","volume":"116","author":"Lenon","year":"2008","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bioorg.2021.104890_b0275","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1517\/14740338.4.6.1005","article-title":"Celecoxib, and cardiovascular risks","volume":"4","author":"Brophy","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.bioorg.2021.104890_b0280","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/archinte.165.2.161","article-title":"The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus","volume":"165","author":"Sowers","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bioorg.2021.104890_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2019.05.040","article-title":"5-Chlorobenzofuran-2-carboxamides: From allosteric CB1 modulators to potential apoptotic antitumor agents","volume":"177","author":"Youssif","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104890_b0290","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejmech.2019.05.015","article-title":"Synthesis and biological evaluation of novel xanthine derivatives as potential apoptotic antitumor agents","volume":"176","author":"Hisham","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104890_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104260","article-title":"Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAFV600E dual inhibitors","volume":"104","author":"Al-Wahaibi","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.104890_b0300","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1107\/S2053230X16014230","article-title":"Crystal structure of rofecoxib bound to human cyclooxygenase-2","volume":"72","author":"Orlando","year":"2016","journal-title":"Acta Crystallogr. F Struct. Biol. Commun."},{"key":"10.1016\/j.bioorg.2021.104890_b0305","unstructured":"Molecular Operating Environment (MOE), Version 2008.10, Chemical Computing Group, Inc. Montreal, Quebec, Canada. http:\/\/www.chemcomp.com."},{"key":"10.1016\/j.bioorg.2021.104890_b0310","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/384644a0","article-title":"Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents","volume":"384","author":"Kurumbail","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2021.104890_b0315","doi-asserted-by":"crossref","first-page":"46265","DOI":"10.1074\/jbc.M207135200","article-title":"Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor","volume":"277","author":"Stamos","year":"2002","journal-title":"J. Biol. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821002674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821002674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:16:56Z","timestamp":1758615416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206821002674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":63,"alternative-id":["S0045206821002674"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.104890","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of new pyrimidine-5-carbonitrile derivatives bearing 1,3-thiazole moiety as novel anti-inflammatory EGFR inhibitors with cardiac safety profile","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.104890","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104890"}}